No article text was recorded for this version.
therapeutic immunogenicity
Version 2 of 289 papers113 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Protein re-surfacing of E. coli L-Asparaginase to evade pre-existing anti-drug antibodies and hypersensitivity responses
- Blog: Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer
- Blog: Humanization of antibodies using a machine learning approach on large-scale repertoire data
- Blog: AI-Guided Precision in Antibody Humanization: Structural Modeling to Minimize Immunogenicity and Preserve Efficacy
- Blog: NBD delivery improves the disease phenotype of the golden retriever model of Duchenne muscular dystrophy
- Blog: Development of therapeutic antibodies for the treatment of diseases
- Blog: A comparison of the binding sites of antibodies and single-domain antibodies
- Blog: Optimization of anti-cobratoxins for treatment of neurotoxic envenomings
- Blog: Humatch - fast, gene-specific joint humanisation of antibody heavy and light chains
- Blog: RGD-avidin–biotin pretargeting to αvβ3 integrin enhances the proapoptotic activity of TNFα related apoptosis inducing ligand (TRAIL)
- Blog: The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains
- Blog: Solid Tumor-Targeted Infiltrating Cytotoxic T Lymphocytes Retained by a Superantigen Fusion Protein
- Blog: Assessing antibody and nanobody nativeness for hit selection and humanization with AbNatiV
- Blog: Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions
- Blog: Hallucinating structure-conditioned antibody libraries for target-specific binders
- Blog: Microenvironment-dependent growth of Sezary cells in humanized IL-15 mice
- Blog: In Vivo Targeted MR Imaging of Endogenous Neural Stem Cells in Ischemic Stroke
- Blog: Construction of Spleen-Accumulated Polysorbate 20-Containing Ionizable Lipid Nanoparticles for mRNA Delivery
- Blog: Design of highly functional genome editors by modelling CRISPR–Cas sequences
- Blog: The allosteric modulation of Complement C5 by knob domain peptides
- Blog: Sterically chained amino acid-rich water-soluble carbon quantum dots as a robust tumor-targeted drug delivery platform
- Blog: PlyNJ3: a three-domain endolysin with broad-spectrum anti-streptococcal activity and synergistic efficacy against multidrug-resistant Streptococcus suis
- Blog: 426 ES005, a high affinity anti-LAG3 monoclonal antibody, inhibits the interactions between LAG3 and multiple ligands and enhances anti-tumor activity of T cells in preclinical models
- Blog: 1364 Discovery of NXA01, a novel CD24 antibody with tumor selectivity and potent anti-tumor activity
- Blog: Generative Humanization for Therapeutic Antibodies
- Blog: In Vivo Targeted Magnetic Resonance Imaging of Endogenous Neural Stem Cells in the Adult Rodent Brain
- Blog: DoggifAI: a transformer based approach for antibody caninisation
- Blog: Gene therapy in Aβ-induced cell and mouse models of Alzheimer’s disease through compensating defective mitochondrial complex I function
- Blog: Harnessing the evolving CRISPR/Cas9 for precision oncology
- Blog: Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes
- Blog: How to make the most of your masked language model for protein engineering
- Blog: Prostaglandin F2 receptor negative regulator as a potential target for chimeric antigen receptor-T cell therapy for glioblastoma
- Blog: Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines
- Blog: Multibody-Enabled Lysosome-Targeting Drug Conjugates for Target Protein Degradation and Combination Therapy
- Blog: Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial
- Blog: Romiplostim versus Recombinant human thrombopoietin in umbilical cord blood transplantation: a single-center retrospective study
- Blog: The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
- Blog: Humanization of antibodies using a machine learning approach on large-scale repertoire data
- Blog: In vitro stability of therapeutically relevant, internally truncated dystrophins
- Blog: Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds
- Blog: Enhancing the protein fitness of interferon-lambda through computational design and glyco-engineering for prophylactic nasal drugs against respiratory viruses
- Blog: Implementation of Glycan Remodeling to Plant-Made Therapeutic Antibodies
- Blog: Tumor‐Homing Phage Nanofibers for Nanozyme‐Enhanced Targeted Breast Cancer Therapy
- Blog: Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening
- Blog: Odorranalectin Is a Small Peptide Lectin with Potential for Drug Delivery and Targeting
- Blog: Expression of α-β1-β2-ε Soluble Fusion Protein of Clostridium perfringens in Escherichia coli and its Immunogenicity in Mice
- Blog: Application of Artificial Intelligence and Computational Biology in Protein Drug Development
- Blog: Iterative immunogen optimization to focus immune responses on a conserved, subdominant viral epitope
- Blog: Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
- Blog: Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia
- Blog: An in silico method to assess antibody fragment polyreactivity
- Blog: Discovery of Highly Active Kynureninases for Cancer Immunotherapy through Protein Language Model
- Blog: Population-specific design of de-immunized protein biotherapeutics
- Blog: The unique activity of the bone morphogenetic protein TGH4 affects the embryonic development of Trichinella spiralis and the establishment of vaccine protection
- Blog: Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics
- Blog: Options for tracking GFP-Labeled transplanted myoblasts using in vivofluorescence imaging: implications for tracking stem cell fate
- Blog: The Involvement of the RhoA/ROCK Signaling Pathway in Hypersensitivity Reactions Induced by Paclitaxel Injection
- Blog: Inhibition of HBV replication by a fully humanized neutralizing antibody <i>in vivo</i> and <i>in vitro</i>
- Blog: Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy
- Blog: AIR: Inference-Time Refinement for Discrete-Diffusion Antibody Humanization
Showing 60 of 89 papers.
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_therapeutic_immunogenicity_4974f6b4,
title = {therapeutic immunogenicity},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/therapeutic-immunogenicity/rdr_4974f6b4999041e19b9ceb83f06709a9},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}This exact version (version 2, frozen text):
@misc{lacuna_therapeutic_immunogenicity_4974f6b4_v2,
title = {therapeutic immunogenicity},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/therapeutic-immunogenicity/rdr_4974f6b4999041e19b9ceb83f06709a9/v/2},
note = {Version 2, frozen 2026-10-04. Accessed 2026-11-20},
}